[1. Den Boer M.L., Harms D.O., Pieters R., Kazemier K.M., Gobel U., Körholz D., Graubner U., Haas R.J., Jorch N., Spaar H.J., Kaspers G.J., Kamps W.A., Van der Does-Van den Berg A., Van Wering E.R., Veerman A.J., Janka-Schaub G.E.: Patient stratification based on prednisolone-vincristineasparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003, 21, 262-3268.10.1200/JCO.2003.11.03112947061]Search in Google Scholar
[2. Escherich G., Tröger A., Göbel U., Graubner U., Pekrun A., Jorch N., Kaspers G., Zimmermann M., zur Stadt U., Kazemier K., Pieters R., Den Boer M.L., Horstmann M., Janka G.E.: The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97). Haematologica 2011, 96, 854-862.10.3324/haematol.2010.039735310564721330320]Search in Google Scholar
[3. Fedele C., Tothill R.W., McArthur G.A.: Navigating the challenge of tumor heterogeneity in cancer therapy. Cancer Discov 2014, 4,146-148.10.1158/2159-8290.CD-13-104224501303]Search in Google Scholar
[4. Gaurnier-Hausser A., Patel R., Baldwin A.S., May M.J., Mason N.J.: NEMO-binding domain peptide inhibits constitutive NF-kappaB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma. Clin Cancer Res 2011, 17, 4661-4671.10.1158/1078-0432.CCR-10-3310327341321610150]Search in Google Scholar
[5. Hatok J., Babusikova E., Matakova T., Mistuna D., Dobrota D., Racay P.: In vitro assays for the evaluation of drug resistance in tumor cells. Clin Exp Med 2009, 9, 1-7.10.1007/s10238-008-0011-318818983]Search in Google Scholar
[6. Ito D., Frantz A.M., Modiano J.F.: Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications. Vet Immunol Immunopathol 2014, 24, 16.]Search in Google Scholar
[7. Ito D., Frantz A.M., Williams C., Thomas R., Burnett R.C., Avery A.C., Modiano J.F.: CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: a tool for in vitro preclinical studies with primary B-cell malignancies. Leuk Lymphoma 2012, 53, 1390-1398.10.3109/10428194.2011.654337372765122229753]Search in Google Scholar
[8. Kaspers G.J., Pieters R., Van Zantwijk C.H., De Laat P.A., De Waal F.C., Van Wering E.R., Veerman A.J.: In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br J Cancer 1991, 64, 469-474.10.1038/bjc.1991.33319776641911186]Search in Google Scholar
[9. Kitada S., Andersen J., Akar S., Zapata J.M., Takayama S., Krajewski S., Wang H.G., Zhang X., Bullrich F., Croce C.M., Rai K., Hines J., Reed J.C.: Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998, 91, 3379-3389.10.1182/blood.V91.9.3379]Search in Google Scholar
[10. Marconato L.: The staging and treatment of multicentric highgrade lymphoma in dogs: a review of recent developments and future prospects. Vet J 2011, 188, 34-38.10.1016/j.tvjl.2010.04.02720627636]Search in Google Scholar
[11. Marconato L., Gelain M.E., Comazzi S.: The dog as a possible animal model for human non-Hodgkin lymphoma: a review. Hematol Oncol 2013, 31, 1-9.10.1002/hon.201722674797]Search in Google Scholar
[12. Matsuda A., Tanaka A., Muto S., Ohmori K., Furusaka T., Jung K., Karasawa K., Okamoto N., Oida K., Itai A., Matsuda H.: A novel NF-kappaB inhibitor improves glucocorticoid sensitivity of canine neoplastic lymphoid cells by up-regulating expression of glucocorticoid receptors. Res Vet Sci 2010, 89, 378-382.10.1016/j.rvsc.2010.03.017]Search in Google Scholar
[13. Mosmann T.: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65, 55-63.10.1016/0022-1759(83)90303-4]Search in Google Scholar
[14. Pawlak A., Rapak A., Drynda A., Poradowski D., Zbyryt I., Dzimira S., Suchański J., Obmińska-Mrukowicz B.: Immunophenotypic characterization of canine malignant lymphoma: a retrospective study of cases diagnosed in Poland Lower Silesia, over the period 2011-2013. Vet Comp Oncol 2014 doi: 10.1111/vco.12112.10.1111/vco.12112]Search in Google Scholar
[15. Pawlak A., Rapak A., Zbyryt I., Obminska-Mrukowicz B.: The effect of common antineoplastic agents on induction of apoptosis in canine lymphoma and leukemia cell lines. In Vivo 2014, 28, 843-850.]Search in Google Scholar
[16. Pieters R., Huismans D.R., Loonen A.H., Hählen K., van der Does-van den Berg A., van Wering E.R., Veerman A.J.: Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 1991, 338, 399-403.10.1016/0140-6736(91)91029-T]Search in Google Scholar
[17. Price G.S., Page R.L., Fischer B.M., Levine J.F., Gerig T.M.: Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapy in dogs with multicentric lymphosarcoma. J Vet Intern Med 1991, 5, 259-262.10.1111/j.1939-1676.1991.tb03131.x1748977]Search in Google Scholar
[18. Seiser E.L., Thomas R., Richards K.L., Kelley M.K., Moore P., Suter S.E., Breen M.: Reading between the lines: molecular characterization of five widely used canine lymphoid tumour cell lines. Vet Comp Oncol 2013, 11, 30-50.10.1111/j.1476-5829.2011.00299.x22236332]Search in Google Scholar
[19. Styczynski, J., Wysocki M.: Is the in vitro drug resistance profile the strongest prognostic factor in childhood acute lymphoblastic leukemia? J Clin Oncol 2004, 5, 963-964.10.1200/JCO.2004.99.27414990658]Search in Google Scholar
[20. Vaughan A., Johnson J.L., Williams L.E.: Impact of chemotherapeutic dose intensity and hematologic toxicity on first remission duration in dogs with lymphoma treated with a chemoradiotherapy protocol. J Vet Intern Med 2007, 21, 1332-1339.10.1111/j.1939-1676.2007.tb01956.x]Search in Google Scholar
[21. Zandvliet M., Teske E., Schrickx J.A.: Multi-drug resistance in a canine lymphoid cell line due to increased P-glycoprotein expression, a potential model for drug-resistant canine lymphoma. Toxicol In Vitro 2014, 28, 1498-1506.10.1016/j.tiv.2014.06.00424975508]Search in Google Scholar